IL-10 Inducing Polypeptides for Inflammatory Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches using high-dose recombinant human IL-10 are limited by side effects and antibody development, making it challenging to effectively induce IL-10 secretion for treating inflammatory and autoimmune disorders.
Innovation Solution
Development of specific polypeptides with amino acid sequences capable of inducing or enhancing IL-10 secretion from human cells, such as those following the general formula SCX1X2X3YLX4, which can stimulate IL-10 production without the need for high-dose recombinant human IL-10 administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If high-dose recombinant human IL-10 is administered to induce IL-10 secretion, then IL-10 levels are improved, but side effects and antibody development worsen
Solution Approach 1:
The patent uses a bacterial peptide (e.g., from Lactobacillus or Bifidobacterium) as an intermediary substance that indirectly stimulates host cells to produce IL-10. Instead of directly administering high doses of recombinant IL-10, the bacterial peptide acts as a mediator that triggers the host's own immune cells (monocytes, macrophages, dendritic cells) to secrete IL-10, thereby achieving therapeutic IL-10 levels without the harmful effects of direct high-dose administration
Solution Approach 2:
The invention enables the host's immune system to serve itself by producing IL-10 in response to bacterial peptide stimulation. The host cells (particularly monocytes and macrophages) are activated by the bacterial peptide to autonomously secrete IL-10, reducing dependency on external recombinant IL-10 administration and avoiding the formation of neutralizing antibodies against therapeutic IL-10
2Reliability
If high-dose recombinant human IL-10 is administered to treat inflammatory disorders, then therapeutic effect is improved, but treatment complexity and safety profile worsen
Solution Approach 1:
The patent employs a simple bacterial peptide that can be easily produced and administered. This short-acting peptide is administered in a way that triggers a sustained IL-10 response without requiring complex dosing regimens or monitoring systems. The peptide itself is inexpensive to produce compared to recombinant IL-10, simplifying the overall treatment approach
Data Source
AI summary
The present invention relates to polypeptides, which are capable of inducing and/or enhancing secretion of IL-10 from human cells. Accordingly, the present invention provides polypeptides, which stimulate IL-10 release from human immune cells. The present invention also relates to nucleic acids encoding such polypeptide, cells expressing such polypeptide, respective pharmaceutical compositions and uses thereof.